deliv slight beat driver mix known
adopt challeng impact commerci result
lower lower net sale prior
slower adopt increas spend drive pt
sale slight beat driver mix transmed report net sale
vs mse gross ww lung sale mse
stock drove weaker sale compani work logist
challeng adopt discuss gross ww heart sale
mse driven ex us increas util
stock us heart declin q/q vs gross basi
due stock longer expect open new clinic site gross
ww liver sale beat mse driven faster expect
enrol oc protect trial complet enrol
pleas see exhibit breakdown sale estim organ
guidanc unchang guidanc unchang impli
net sale comfort midpoint rang
impli sale q/q weaker
driven follow oc liver revenu liver pivot
complet earli compani wait liver protect cap dcd
begin sequenti declin us lung us heart due
stock logist challeng oc adopt discuss leav
us conserv outlook model gross us lung vs
gross us heart vs
slower adopt curv impact outlook oc paradigm chang
technolog organ transplant show earli sign traction amongst
kol hospit onboard physician train reimburs challeng
shift clinic commerci present challeng take time work
issu new us driver equal-
weight rate ipo see said logist challeng impact
near term adopt evidenc limit ytd improv us
quarterli sale see exhibit requir greater invest
transmed overcom near intermedi term lower
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
net sale vs prior driven mostli
decreas pace adopt us oc lung lower
vs prior decreas
increas opex still project ebitda break-even
model ebitda margin vs prior pleas see exhibit
model chang
clinic updat focus liver heart heart fda panel
expect sometim offici date set oc heart
approv may slip pend time panel oc liver protect trial
complet interim look data present atc
may transmed expect begin cap new dcd liver trial
pleas see initi deep dive market size driver growth
remain equal-weight pt thesi base risk-adjust
penetr multibillion dollar market expand pathway
potenti posit clinic data regulatori catalyst given earli
stage commerci launch number upcom regulatori approv
us see exist valuat offer balanc pictur signific
opportun risk taper expect adopt curv
increas expect invest channel develop lower pt
prior pt base base case sale
impli sale support dcf assum
penetr lung heart prior penetr liver
oper margin prior wacc prior
posit risk reward driven catalyst pathway potenti expans
risk reward driven catalyst pathway potenti expans
price target reflect multipl
base case sale high growth smid cap devic
peer support dcf wacc ww
penetr oc lung/heart assum sale grow
compound-annual-growth-rate driven differenti clinic econom valu
oc momentum inflect faster sale revis higher multipl
expand oc lung heart adopt acceler fda approv
data inspir heart expand prove compel tam
expans increas lsd-msd msd-hsd penetr increas
pt us lung us heart oc us liver adopt
acceler doubl investor give credit liver given tam
ev/sal support dcf
ev/sal support dcf
oc potenti redefin organ transplant potenti improv
outcom cost econom suppli expans drive util oc lung
adopt standard criteria lung drive growth adopt expand
criteria lung drive adopt oc heart adopt standard
expand criteria heart drive adopt ev/sal multipl
peer group justifi peer growth prospect
switch commerci take longer expect upcom clinic data
point less compel limit regulatori approv adopt oc
drive increas volum penetr decreas pt
us lung us heart us liver adopt delay
clinic trial fall valuat multipl contract still recogn
growth potenti multibillion dollar
transmed oc paradigm chang
technolog allow market expans
sub-optimal organ donor pool extend
organ viabl transplant time pre-
screen organ function decreas
us heart/lung market
intermedi term oc grow transplant
volum lsd-msd annual
revenu growth driven oc
lung/heart limit contribut
data trial demonstr improv
outcom better cost econom vs
standard care drive increas physician
everi bp ww oc heart lung
combin penetr estim
gross margin increas
inspir long term data oc liver
risk achiev price
channel develop occur faster
slower pace physician adopt
less limit lead greater lower oc
fda heart panel posit potenti
reimburs prove less
rate limit util expect
data key trial demonstr
meaning better wors outcom
chang net work capit
pv free flow
growth work capit
perpetu growth rate
equiti
after-tax cost debt
total discount valu
discount valu nol
sale
sale
sale
sale
dollar million except per share data
invest
st debt current portion lt debt
dollar million except per share data
net chang work capit
net invest
chg short-term debt
chg long-term debt
chang equiti
effect exchang rate chang
net financ
begin period
end period
